Education
About Us
Working with TipRanks
Follow Us
Fresenius Se (FSNUY)
OTHER OTC:FSNUY
Top Page
Fresenius SE & Co
(OTC:FSNUY)
Select Model
Select Model
Rating:70Outperform
Price Target:
$15.50
▲(10.40% Upside)
Fresenius SE & Co's overall stock score is driven by strong financial performance and a positive earnings call, which highlighted significant growth and strategic execution. Technical indicators suggest positive momentum, although valuation metrics indicate the stock is fairly valued. The company faces some macroeconomic challenges, but its strategic focus and operational execution provide a solid foundation for future growth.
Positive Factors
Revenue Growth
Consistent revenue growth indicates strong market demand and effective business strategies, supporting long-term expansion and stability.
Operational Execution
Effective cost management and operational execution enhance profitability, providing a solid foundation for sustainable growth.
Cash Flow Generation
Strong cash flow generation enhances financial flexibility, enabling strategic investments and debt reduction, bolstering long-term resilience.
Negative Factors
Macroeconomic Challenges
Persistent macroeconomic and geopolitical challenges can impact operational costs and revenue, posing risks to sustained growth.
DRG Inflator in Germany
Lower DRG inflator projections may reduce revenue growth in Germany, affecting the profitability of the hospital management segment.
Impact of U.S. Tariffs
U.S. tariffs increase costs for Kabi, particularly in MedTech, potentially squeezing margins and impacting competitive positioning.
Fresenius SE & Co (FSNUY) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$32.00B
Dividend Yield1.97%
Average Volume (3M)1.96K
Price to Earnings (P/E)25.3
Beta (1Y)0.19
Revenue Growth2.59%
EPS GrowthN/A
CountryUS
Employees175,202
SectorHealthcare
Sector Strength45
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)0.18
Shares Outstanding2,252,949,200
10 Day Avg. Volume0
30 Day Avg. Volume1,958
Financial Highlights & Ratios
PEG Ratio-0.89
Price to Book (P/B)3.90
Price to Sales (P/S)3.49
P/FCF Ratio49.97
Enterprise Value/Market Cap4.37
Enterprise Value/Revenue6.01
Enterprise Value/Gross Profit24.08
Enterprise Value/Ebitda38.55
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Fresenius SE & Co Business Overview & Revenue Model
Company DescriptionFresenius SE & Co. KGaA is a global healthcare group based in Germany, operating in the sectors of dialysis, hospital management, and pharmaceuticals. The company is primarily known for its medical devices and services related to renal care, particularly through its Fresenius Medical Care division, which is the world's largest provider of dialysis products and services. Additionally, Fresenius operates in the pharmaceutical sector via Fresenius Kabi, focusing on injectable drugs and clinical nutrition, and in hospital management through Fresenius Helios, which manages a network of hospitals in Germany.
How the Company Makes MoneyFresenius generates revenue through multiple streams primarily from its three divisions: Fresenius Medical Care, Fresenius Kabi, and Fresenius Helios. Fresenius Medical Care makes money by providing dialysis services and selling dialysis products, including machines and consumables to healthcare facilities and home patients. Fresenius Kabi earns revenue from its portfolio of generic injectable drugs, infusion therapies, and clinical nutrition products, often selling to hospitals and healthcare providers. Fresenius Helios contributes by operating hospitals and outpatient facilities, generating revenue from patient care services. Additionally, strategic partnerships with healthcare organizations and a focus on expanding their product offerings in emerging markets further enhance their revenue potential.
Fresenius SE & Co Earnings Call Summary
Earnings Call Date:Nov 05, 2025
(Q3-2025)
| % Change Since: |
Next Earnings Date:Feb 25, 2026
Earnings Call Sentiment Positive
Fresenius demonstrated strong performance across its core businesses, with significant EPS growth and an EBIT guidance upgrade. Despite facing macroeconomic and geopolitical challenges, the company maintained strong operational execution, particularly in its Kabi and biopharma segments. The DRG inflator in Germany and U.S. tariffs present potential headwinds, but the overall momentum remains positive.Q3-2025 Updates
Positive Updates
EBIT Guidance Upgrade
Fresenius raised its full-year EBIT growth guidance from 3%-7% to 4%-8%, reflecting successful execution of its strategy and strong momentum.
Strong Core EPS Growth
Core EPS grew by an impressive 14%, significantly outpacing top-line growth, highlighting effective cost management and operational execution.
Kabi's Performance
Kabi achieved an excellent 16.7% EBIT margin with strong contributions from newly launched products and pipeline progress, particularly in IV generics and biosimilars.
Biopharma Growth
Biopharma reported a 37% organic growth with strong market traction, and achieved key milestones such as FDA interchangeability designation for denosumab.
Strong Cash Flow
Operating cash flow reached EUR 2.2 billion, supporting the company's deleveraging efforts and capital allocation framework.
Negative Updates
Macroeconomic and Geopolitical Challenges
The company faced ongoing macroeconomic volatility and geopolitical tensions, although it managed to navigate these challenges effectively.
DRG Inflator in Germany
The projected DRG inflator for 2026 is anticipated to be lower than expected due to methodology changes, potentially impacting future revenue growth in Germany.
Impact of U.S. Tariffs
Kabi continued to absorb adverse effects from U.S. tariffs, particularly affecting MedTech, despite the potential exemption for generics and biosimilars.
Company Guidance
In the recent earnings call, Fresenius provided an optimistic update, raising its full-year EBIT growth guidance from 3%-7% to 4%-8%. This upgrade reflects the company's strong performance, particularly in the third quarter, where core EPS grew by an impressive 14%, significantly outpacing top-line growth. Key drivers of this success include Kabi's robust profitability with a 16.7% EBIT margin, driven by newly launched products and pipeline progress, especially in IV generics and biosimilars. Helios also delivered a solid quarter, maintaining a strong EBIT margin. The company highlighted its strategic focus on its "Rejuvenate" phase, which aims to upgrade core operations and scale platforms to achieve long-term growth. This strategy is supported by strong cash flow delivery, enabling Fresenius to stay within its target leverage corridor. The call also addressed the impact of macroeconomic factors, such as geopolitical tensions and tariffs, but emphasized the company's adaptive and focused strategy to navigate these challenges effectively.Fresenius SE & Co Financial Statement Overview
Summary
Fresenius SE & Co has shown solid revenue growth and improved profitability, with a healthy gross profit margin of 25.4% and a net profit margin of 5.06%. The balance sheet is stable with a debt-to-equity ratio of 0.70, but past high leverage levels pose risks. Cash flow generation is robust, though historical volatility suggests potential challenges.Income Statement
Fresenius SE & Co has shown a solid revenue growth rate of 4.69% in the TTM, recovering from previous declines. The gross profit margin is healthy at 25.4%, and the net profit margin has improved to 5.06%, indicating better profitability. However, historical fluctuations in revenue growth and net income suggest some volatility.Balance Sheet
The company's debt-to-equity ratio has improved to 0.70, indicating a more balanced leverage compared to previous years. Return on equity is modest at 5.92%, reflecting moderate profitability. The equity ratio stands at 43.8%, showing a stable financial structure. However, past high leverage levels pose potential risks.Cash Flow
Operating cash flow is strong, with a positive operating cash flow to net income ratio of 0.27. Free cash flow growth is positive at 2.94%, recovering from previous declines. The free cash flow to net income ratio of 0.56 indicates efficient cash generation. However, historical volatility in cash flow growth rates suggests potential instability.| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 23.27B | 21.83B | 22.30B | 40.84B | 37.52B | 36.28B |
| Gross Profit | 5.80B | 5.38B | 5.06B | 10.72B | 10.31B | 10.32B |
| EBITDA | 3.62B | 3.14B | 2.73B | 3.09B | 6.84B | 7.19B |
| Net Income | 1.20B | 471.00M | -594.00M | 1.37B | 1.82B | 1.71B |
Balance Sheet | ||||||
| Total Assets | 49.89B | 43.55B | 45.28B | 76.42B | 71.96B | 66.65B |
| Cash, Cash Equivalents and Short-Term Investments | 2.78B | 2.05B | 2.56B | 2.35B | 2.75B | 2.00B |
| Total Debt | 15.91B | 13.58B | 15.83B | 27.76B | 27.16B | 25.91B |
| Total Liabilities | 27.25B | 23.26B | 25.63B | 44.20B | 42.67B | 40.62B |
| Stockholders Equity | 21.88B | 19.54B | 19.00B | 20.41B | 19.00B | 16.95B |
Cash Flow | ||||||
| Free Cash Flow | 1.27B | 1.52B | 3.32B | 2.28B | 3.03B | 4.14B |
| Operating Cash Flow | 2.31B | 2.45B | 4.46B | 4.20B | 5.08B | 6.55B |
| Investing Cash Flow | -768.74M | -510.00M | -3.19B | -2.61B | -2.82B | -3.01B |
| Financing Cash Flow | -530.95M | -2.18B | -1.38B | -1.60B | -1.45B | -3.12B |
Fresenius SE & Co Technical Analysis
Positive
14.04
Price Trends
14.04
Positive
13.94
Positive
12.93
Positive
Market Momentum
0.13
Negative
64.63
Neutral
89.07
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FSNUY, the sentiment is Positive. The current price of 14.04 is below the 20-day moving average (MA) of 14.25, above the 50-day MA of 14.04, and above the 200-day MA of 12.93, indicating a bullish trend. The MACD of 0.13 indicates Negative momentum. The RSI at 64.63 is Neutral, neither overbought nor oversold. The STOCH value of 89.07 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FSNUY.
Fresenius SE & Co Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | $12.93B | 9.84 | 19.97% | 0.35% | 10.21% | 39.58% | |
74 Outperform | $17.68B | 13.68 | 34.51% | ― | -0.56% | -53.50% | |
70 Outperform | $32.00B | 25.35 | 7.22% | 1.97% | 2.59% | ― | |
70 Neutral | $107.72B | 18.24 | ― | 0.61% | 6.82% | 15.82% | |
65 Neutral | $13.38B | 16.73 | 5.31% | 3.29% | 4.09% | 13.17% | |
59 Neutral | $7.87B | 11.34 | ― | ― | 5.14% | 4.37% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
FSNUY
Fresenius SE & Co
14.81
5.99
67.85%
DVA
DaVita
110.10
-51.90
-32.04%
FMS
Fresenius Medical Care
23.84
1.62
7.29%
HCA
HCA Healthcare
474.32
170.81
56.28%
THC
Tenet Healthcare
199.61
71.98
56.40%
UHS
Universal Health
205.96
22.56
12.30%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.